{
  "id": 20568366,
  "title": "Lotte Biologics completes construction of production plant in Incheon, eyes global expansion",
  "url": "https://urgent.news/2026/11/18/lotte-biologics-completes-construction-of-production-plant-in-incheon-20568366",
  "topic": "world",
  "section": "World",
  "published": "2026-11-18T08:37:03.000Z",
  "source": {
    "name": "The Korea Times",
    "slug": "the-korea-times",
    "url": "https://www.koreatimes.co.kr/business/companies/20261118/lotte-biologics-completes-construction-of-production-plant-in-incheon-eyes-global-expansion"
  },
  "original_language": "en",
  "account": "Lotte Biologics marked a significant milestone in its quest to become a key player in the global biopharmaceutical industry by completing construction of its biomanufacturing facility in Incheon, South Korea on Wednesday. The company showcased this achievement at a completion ceremony for Plant 1, located at their Songdo Bio Campus. Notable attendees included co-chief executives James Park and Shin Yoo-yeol, along with Lotte Group Chairman Shin Dong-bin.\n\nChairman Shin highlighted that the biopharmaceutical business is the future growth engine of the Lotte Group and a next-generation industry poised to propel Korea into the future. The production plant, covering a sprawling 100,000 square meters, is a state-of-the-art facility equipped with critical components such as a production building and a wastewater treatment plant. With an annual production capacity of 120,000 liters, the facility is expected to commence commercial operations in 2028, according to the company's official statements.\n\nThis new plant is poised to serve as a large-scale production base for Lotte Biologics in Korea, complementing their recently acquired manufacturing facility in Syracuse, New York, which they incorporated into their operations in 2023.",
  "summary": "Lotte Biologics completed construction of its biomanufacturing facility in Incheon, just west of Seoul, on Wednesday, marking a major step in its efforts to become a leading player in the global biopharmaceutical market. A completion ceremony for Plant 1, located at the company's Songdo Bio Campus in Incheon, was attended by the company's co-chief executive officers, James Park and Shin Yoo-yeol,…",
  "key_points": [
    "Lotte Biologics completes Incheon plant construction on Wednesday.",
    "Plant 1 covers 100,000 sq meters with 120,000L annual capacity.",
    "Facility set to begin commercial operations in 2028."
  ],
  "editors_take": "Establishing this large-scale production base in South Korea positions Lotte Group to transform the biopharmaceutical sector into a primary growth engine for its future global expansion.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Yonhap News",
        "title": "Lotte Biologics completes construction of production plant in Incheon, eyes global expansion",
        "url": "https://urgent.news/2026/11/18/lotte-biologics-completes-construction-of-production-plant-in-incheon",
        "published": "2026-11-18T05:08:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}